Open Access compliance and financial report to RCUK 2015-16

This report provides information in support of Northumbria University’s compliance with the third year of RCUK’s Open Access policy within the context of the University’s wider work to support Open Access (OA) as part of its mission to create and apply knowledge for the benefit of individuals and the economy through ground-breaking research. The data underlying this report is available on Figshare: https://dx.doi.org/10.6084/m9.figshare.3859023.v

Optimising Resources to Develop a Strategic Approach to Open Access - final report

Our Open Access (OA) Pathfinder, a collaboration between the University of Northumbria and the University of Sunderland, aimed to develop and share tools and best practice to enable HEIs with limited external resources to effectively and creatively respond to the challenges and opportunities presented by OA. To achieve this we identified four discrete project objectives and a methodology which emphasised engagement locally and with the other HEI’s that comprised the wider programme. Importantly, the wider context of this focus was our recognition of the global movement towards open research and an impact agenda which demonstrates and rewards value for money from public investment. Subsequently, throughout our project activity we aimed to explore and develop extensible models, policies and procedures which go beyond OA compliance to engage with and shape these wider debates. Throughout the programme we disseminated our preliminary findings and ongoing thinking via our project blog (http://oapathfinder.wordpress.com) as well as fora including conferences and workshops. By the end of the two year programme, our project had successfully delivered against the four objectives and in so doing demonstrated tangible impact. Crucially, for each aspect of our project further work is needed to refine and develop solutions and practice to meet the challenges and opportunities presented by OA. We believe that against a background of a rapidly evolving policy and funding landscape JISC are uniquely positioned to facilitate a community of practice to play a pivotal role in making this happen

The Coexistence of Natural and Supernatural Explanations Across Cultures and Development

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91141/1/j.1467-8624.2012.01743.x.pd

WFPC2 Observations of Leo A: A Predominantly Young Galaxy within the Local Group

The unprecedented detail of the WFPC2 colour-magnitude diagrams of the resolved stellar population of Leo A presented here allows us to determine a new distance and an accurate star formation history for this extremely metal-poor Local Group dwarf irregular galaxy. From the position of the red clump, the helium-burning blue loops and the tip of the red giant branch, we obtain a distance modulus, m-M=24.2+/-0.2, or 690 +/- 60 kpc, which places Leo A firmly within the Local Group. Our interpretation of these features in the WFPC2 CMDs at this new distance based upon extremely low metallicity (Z=0.0004) theoretical stellar evolution models suggests that this galaxy is predominantly young, i.e. <2 Gyr old. A major episode of star formation 900 - 1500 Gyr ago can explain the red clump luminosity and also fits in with our interpretation of the number of anomalous Cepheid variable stars seen in this galaxy. We cannot rule out the presence of an older, underlying globular cluster age stellar population with these data. However, using the currently available stellar evolution models, it would appear that such an older population is limited to no more than 10% of the total star formation to have occured in this galaxy. Leo A provides a nearby laboratory for studying young metal poor stars and investigations of metal-poor galaxy evolution, such as is supposed to occur for larger systems at intermediate and high redshifts.Comment: 64 pages, 18 figures, 4 tables accepted for publication in the Astronomical Journal (Sept. 98

The range and level of impurities in CO2 streams from different carbon capture sources

For CO2 capture and storage deployment, the impact of impurities in the gas or dense phase CO2 stream arising from fossil fuel power plants, or large scale industrial emitters, is of fundamental importance to the safe and economic transportation and storage of the captured CO2. This paper reviews the range and level of impurities expected from the main capture technologies used with fossil-fuelled power plants in addition to other CO2 emission-intensive industries. Analysis is presented with respect to the range of impurities present in CO2 streams captured using pre-combustion, post-combustion and oxy-fuel technologies, in addition to an assessment of the different parameters affecting the CO2 mixture composition. This includes modes of operation of the power plant, and different technologies for the reduction and removal of problematic components such as water and acid gases (SOx/NOx). A literature review of data demonstrates that the purity of CO2 product gases from carbon capture sources is highly dependent upon the type of technology used. This paper also addresses the CO2 purification technologies available for the removal of CO2 impurities from raw oxy-fuel flue gas, such as Hg and non-condensable compounds. CO2 purities of over 99% are achievable using post-combustion capture technologies with low levels of the main impurities of N2, Ar and O2. However, CO2 capture from oxy-fuel combustion and integrated gasification combined cycle power plants will need to take into consideration the removal of non-condensables, acid gas species, and other contaminants. The actual level of CO2 purity required will be dictated by a combination of transport and storage requirements, and process economics

The Serotonin-6 Receptor as a Novel Therapeutic Target

Serotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter that is found in both the central and peripheral nervous systems. 5-HT mediates its diverse physiological responses through 7 different 5-HT receptor families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors. Among them, the 5-HT6 receptor (5-HT6R) is the most recently cloned serotonin receptor and plays important roles in the central nervous system (CNS) and in the etiology of neurological diseases. Compared to other 5-HT receptors, the 5-HT6R has been considered as an attractive CNS therapeutic target because it is expressed exclusively in the CNS and has no known isoforms. This review evaluates in detail the role of the 5-HT6R in the physiology and pathophysiology of the CNS and the potential usefulness of 5-HT6R ligands in the development of therapeutic strategies for the treatment of CNS disorders. Preclinical studies provide support for the use of 5-HT6R ligands as promising medications to treat the cognitive dysfunction associated with Alzheimer's disease, obesity, depression, and anxiety

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

BACKGROUND: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is well tolerated and immunogenic in SARS-CoV-2 seronegative and seropositive individuals aged 18-75. METHODS: A phase 2a expanded safety and immunogenicity study of a saRNA SARS-CoV-2 vaccine candidate LNP-nCoVsaRNA, was conducted at participating centres in the UK between 10th August 2020 and 30th July 2021. Participants received 1 μg then 10 μg of LNP-nCoVsaRNA, ∼14 weeks apart. Solicited adverse events (AEs) were collected for one week post-each vaccine, and unsolicited AEs throughout. Binding and neutralisating anti-SARS-CoV-2 antibody raised in participant sera was measured by means of an anti-Spike (S) IgG ELISA, and SARS-CoV-2 pseudoneutralisation assay. (The trial is registered: ISRCTN17072692, EudraCT 2020-001646-20). FINDINGS: 216 healthy individuals (median age 51 years) received 1.0 μg followed by 10.0 μg of the vaccine. 28/216 participants were either known to have previous SARS-CoV2 infection and/or were positive for anti-Spike (S) IgG at baseline. Reactogenicity was as expected based on the reactions following licensed COVID-19 vaccines, and there were no serious AEs related to vaccination. 80% of baseline SARS-CoV-2 naïve individuals (147/183) seroconverted two weeks post second immunization, irrespective of age (18-75); 56% (102/183) had detectable neutralising antibodies. Almost all (28/31) SARS-CoV-2 positive individuals had increased S IgG binding antibodies following their first 1.0 μg dose with a ≥0.5log10 increase in 71% (22/31). INTERPRETATION: Encapsulated saRNA was well tolerated and immunogenic in adults aged 18-75 years. Seroconversion rates in antigen naïve were higher than those reported in our dose-ranging study. Further work is required to determine if this difference is related to a longer dosing interval (14 vs. 4 weeks) or dosing with 1.0 μg followed by 10.0 μg. Boosting of S IgG antibodies was observed with a single 1.0 μg injection in those with pre-existing immune responses. FUNDING: Grants and gifts from the Medical Research Council UKRI (MC_PC_19076), the National Institute for Health Research/Vaccine Task Force, Partners of Citadel and Citadel Securities, Sir Joseph Hotung Charitable Settlement, Jon Moulton Charity Trust, Pierre Andurand, and Restore the Earth

Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.

BACKGROUND: The scale of the 2022 global mpox (formerly known as monkeypox) outbreak has been unprecedented. In less than 6 months, non-endemic countries have reported more than 67 000 cases of a disease that had previously been rare outside of Africa. Mortality has been reported as rare but hospital admission has been relatively common. We aimed to describe the clinical and laboratory characteristics and outcomes of individuals admitted to hospital with mpox and associated complications, including tecovirimat recipients. METHODS: In this cohort study, we undertook retrospective review of electronic clinical records and pathology data for all individuals admitted between May 6, and Aug 3, 2022, to 16 hospitals from the Specialist and High Consequence Infectious Diseases Network for Monkeypox. The hospitals were located in ten cities in England and Northern Ireland. Inclusion criteria were clinical signs consistent with mpox and MPXV DNA detected from at least one clinical sample by PCR testing. Patients admitted solely for isolation purposes were excluded from the study. Key outcomes included admission indication, complications (including pain, secondary infection, and mortality) and use of antibiotic and anti-viral treatments. Routine biochemistry, haematology, microbiology, and virology data were also collected. Outcomes were assessed in all patients with available data. FINDINGS: 156 individuals were admitted to hospital with complicated mpox during the study period. 153 (98%) were male and three (2%) were female, with a median age of 35 years (IQR 30-44). Gender data were collected from electronic patient records, which encompassed full formal review of clincian notes. The prespecified options for data collection for gender were male, female, trans, non-binary, or unknown. 105 (71%) of 148 participants with available ethnicity data were of White ethnicity and 47 (30%) of 155 were living with HIV with a median CD4 count of 510 cells per mm3 (IQR 349-828). Rectal or perianal pain (including proctitis) was the most common indication for hospital admission (44 [28%] of 156). Severe pain was reported in 89 (57%) of 156, and secondary bacterial infection in 82 (58%) of 142 individuals with available data. Median admission duration was 5 days (IQR 2-9). Ten individuals required surgery and two cases of encephalitis were reported. 38 (24%) of the 156 individuals received tecovirimat with early cessation in four cases (two owing to hepatic transaminitis, one to rapid treatment response, and one to patient choice). No deaths occurred during the study period. INTERPRETATION: Although life-threatening mpox appears rare in hospitalised populations during the current outbreak, severe mpox and associated complications can occur in immunocompetent individuals. Analgesia and management of superimposed bacterial infection are priorities for patients admitted to hospital. FUNDING: None